Sidewinder pockets $137m in Series B to take bispecific ADCs to clinic
Sidewinder Therapeutics has secured $137m in a Series B financing round to progress its pipeline of bispecific antibody-drug conjugates (ADCs)…
08 Apr 2026
RoosterBio and MineBio team up to expand MSC solutions access in China
RoosterBio has entered an exclusive distributor partnership with MineBio Life Sciences to expand access to scalable, research-grade and current good manufacturing practice (cGMP)-grade mesenchymal stem cell (MSC) and exosome bioprocessing…
08 Apr 2026
Pharma industry laments Trump’s tariff on branded drugs
The pharmaceutical industry has widely criticised the US administration’s decision to impose a 100% tariff on branded drugs imported into the country, as trade bodies and analysts begin to dissect…
08 Apr 2026
Halozyme and Vertex sign deal for Hypercon technology
Halozyme Therapeutics' subsidiary Halozyme Hypercon has signed a global exclusive partnership and licence agreement with Vertex Pharmaceuticals for the former's Hypercon technology. Vertex has licensed the technology for use in…
07 Apr 2026
Gilead outlays $5bn to acquire ADC specialist Tubulis
Gilead will acquire antibody-drug conjugate (ADC) developer Tubulis in a deal worth up to $5bn, continuing the big pharma company’s recent string of high-profile M&A activity in 2026. As per…
07 Apr 2026
Apnimed obtains up to $150m in funds for commercial launch of AD109
Apnimed has signed a senior secured credit facility of up to $150m with funds managed by HealthCare Royalty Partners (HCRx) to support the planned launch of AD109. The funding will…
07 Apr 2026
Neurocrine to acquire Soleno in $2.9bn transaction
Neurocrine Biosciences has signed a definitive agreement to acquire Soleno Therapeutics for $53.00 per share in cash, which represents $2.9bn in total transaction equity value. The transaction will expand Neurocrine’s portfolio…